GE Healthcare this week announced the FDA 510(k) clearance of its computed tomography (CT) technology that uses a new reconstruction method to improve image clarity at a lower dose. GE’s Veo represents the CT industry’s first Model-based Iterative Reconstruction Technique (MBIR), according to company officials.
GE Healthcare this week announced the FDA 510(k) clearance of its computed tomography (CT) technology that uses a new reconstruction method to improve image clarity at a lower dose.
GE’s Veo represents the CT industry’s first Model-based Iterative Reconstruction Technique (MBIR), according to company officials. It is housed on GE Discovery CT750 HD systems, and is already available in Europe, Canada, and parts of Asia.
In clinical trials with Veo users in Europe showed “profound image clarity at yet unseen low dose levels,” the company said. Users reported successful chest CTs done with an equivalent amount of radiation as a chest X-ray, or less than one-tenth of one mSv.
The new method, MBIR, complements GE’s Adaptive Statistical Iterative Reconstruction (ASiR) technique.
Conventional reconstructive technology, Filtered-Back Projection (FBP), takes a single pass through the raw data, but doesn’t account for the noise in the image. As a model-based technology, Veo makes a first estimate of the image, then goes back and iterates to compare how accurate it is to the actual CT data. It continues to iterate on that process to refine it to an optimal image, Scott Schubert, GE’s general manager for Premium CT Product Marketing, said in an interview.
Schubert noted that CT has made evolutionary advances in terms of the number of slices and speed, but that image reconstruction hasn’t changed much over time. “This technology is a real breakthrough in terms of moving the CT clarity and the dose performance to a whole new level of capability,” he said.
GE is also coordinating a multi-center study to further evaluate improvements, including lower dose levels, and results are expected to be available later next year.
“Veo’s revolutionary capabilities change the rules of CT imaging, and represent our promise to help eliminate the traditional trade-off between image clarity and low dose levels as we help healthcare professionals offer the best patient care possible,” Steve Gray, vice president and general manager of CT and Advantage Workstation for GE Healthcare, said in a statement.
Courtesy GE Healthcare
For more on MBIR, check out this video with William Shuman, MD, FACR, Professor and Vice Chairman for the Univ. of Washington Department of Radiology, discussing MBIR at the 2011 ISCT meeting in San Francisco.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.